Company: PSTV
Filing Date: 2025-05-02
Form Type: 8-K
Source: 0000950170-25-062742
Chunk: 2

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-05-02
Form: 8-K
Item: Item 5.07
Chunk 2
---
 Warrants (the “ Warrants") and (3) the issuance of 280,421,380 shares of Common Stock that could become issuable upon exercise of the Series A Warrants and 1,261,896,210 shares of Common Stock that could become issuable upon exercise of the Series B Warrants, in each case as a result of certain adjustment provisions set forth in the applicable warrants and assumptions described in the Proxy Statement and subject to the potential for further adjustments. The votes regarding this proposal were as follows:

  Votes For      Votes Against      Abstentions      Broker Non-Votes  
 ───────────────────────────────────────────────────────────────────────
  2,236,313            376,793            5,327             1,368,946  

Proposal No. 3 - Authorized Common Stock Increase Proposal.

As described above in Item 5.03, the Company’s stockholders approved the Authorized Common Stock Increase Proposal. The votes regarding this proposal were as follows:

  Votes For      Votes Against      Abstentions      Broker Non-Votes  
 ───────────────────────────────────────────────────────────────────────
  7,273,240            887,265           15,294                     0  

Proposal No. 4 - Warrant Amendment Proposal.

The Company’s stockholders approved, for purposes of complying with Nasdaq Listing Rule 5635(d), the extension of the term of the Company’s May 2024 Warrants. The votes regarding this proposal were as follows:

  Votes For      Votes Against      Abstentions      Broker Non-Votes  
 ───────────────────────────────────────────────────────────────────────
  6,507,373            291,459            8,021             1,368,946  

Item 8.01 Other Events.

Following the approval of the Issuance Proposal and expiration of a 10-trading-day reset period, the exercise price of the Warrants will be reset to the greater of (i) the lowest single trading day volume weighted average price of the Common Stock during the reset period and (ii) $0.132 (the “ Floor Price”). If the exercise price of the Series A Warrants is reduced to the Floor Price pursuant to the reset provision, the 28,042,138 outstanding Series A Warrants would become exercisable for an aggregate of up to 280,421,380 shares of Common Stock. In addition to the reset provision, the Series B Warrants are subject to